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Summary. This study aimed to assess the distribution of
VEGF-C and VEGFR-3 expression in gastrointestinal
stromal tumours (GISTs), and to analyse the value of
lymphatic vessel density (LVD) in a tumour that is
believed to preferentially metastasize through blood
vessel conduits. A panel of immunohistochemical
antibodies was used to evaluate 51 cases of genetically
characterised GISTs: VEGF-C, VEGFR-3, D2-40 (for
LVD assessment) and CD31 (for blood vessel density –
BDV – assessment). The results were correlated with the
clinical-pathological data. The large majority of cases
(86.2%; 44/51) showed a mutation of the KIT gene, most
of them (72.5%; 37/51) revealing mutations in exon 11.
VEGFR-3 was predominantly expressed in KIT mutated
GISTs (p=0.019). High LVD was correlated with the
absence of metastasis (p=0.010) and high BVD showed
a positive correlation with the occurrence of metastasis
(p=0.049). The strong expression of VEGF-C and
VEGFR-3 in GIST’s cells was not correlated with the
clinical parameters of aggressiveness, nor with high
LVD. 
Key words: Gastrointestinal stromal tumours, KIT, D2-
40, VEGF-C, VEGFR-3
Introduction
Gastrointestinal stromal tumours (GISTs) have a low
frequency that ranges from 10 to 20 cases per million
yearly, and the estimated prevalence is 129 per million
(Blackstein et al., 2006; Corless and Heinrich, 2008;
Stamatakos et al., 2009). They are rarely found in
patients younger than 40 years of age, although there
have been some reports from paediatric populations
(Chourmouzi et al., 2009). Cajal’s cells are recognised as
the precursor cells of GISTs, but presently, there is some
evidence that these tumours may also originate from
multipotential mesenchymal stem cells (Corless and
Heinrich, 2008; Stamatakos et al., 2009). 
Morphologically, GISTs are generally composed of
spindle cells; epithelioid mixed patterns are also
identified (Miettinen et al., 2005; Zhang et al., 2010).
CD117 positive reaction is used to characterise GISTs
and rule out other tumours with similar morphology,
such as sarcomas, mesotheliomas, melanomas and
poorly differentiated carcinomas (Stamatakos et al.,
2009). A commercial immunohistochemical antibody is
used to identify specific epitopes of GISTs (Miettinen et
al., 2006). CD117 protein is the product of c-kit (KIT)
proto-oncogene, which is located in the 4q12
chromosome region (Mushtaq et al., 2009). GISTs
frequently exhibit oncogenic mutations in the KIT gene
and, less commonly, in the PDGFRA gene (Gomes et al.,
2008; Martinho et al., 2009), which is a related gene that
also encodes a type III tyrosine-kinase receptor.
Likewise, PDGFRA mutation is found in circa 5% of
Lymphangiogenic VEGF-C and VEGFR-3 
expression in genetically characterised 
gastrointestinal stromal tumours 
Antônio Talvane Torres de Oliveira1, Rui M. Reis2,3, Julieta Afonso2,4, Olga Martinho2,
Delcio Matos5, André Lopes Carvalho1,3, Vinícius Lima Vazquez1, Thiago Buosi Silva1,
Cristovam Scapulatempo1, Sarhan Sydney Saad5 and Adhemar Longatto-Filho2,6
1Departments of Digestive Surgery and Pathology and Center for Researcher Support, Barretos Cancer Hospital, Pio XII Foundation,
Barretos, São Paulo, Brazil, 2Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho,
Braga, Portugal, 3Molecular Oncology Research Center, Barretos Cancer Hospital, Pio XII Foundation, Barretos, São Paulo, Brazil,
4Alto Ave Superior Institute of Health (ISAVE), Póvoa de Lanhoso, Portugal, 5Department of Gastroenterology, Medical School of the
Federal University of São Paulo (UNIFESP) and 6Laboratory of Medical Investigation (LIM) 14, Department of Pathology, University
of São Paulo School of Medicine, Brazil 
Histol Histopathol (2011) 26: 1499-1507
Offprint requests to: Adhemar Longatto Filho, MSc, PhD, P.M.I.A.C.,
Laboratory of Medical Investigation (LIM) 14, Faculty of Medicine, São
Paulo State University; 01246-903, São Paulo, Brazil. e-mail:
longatto16@hotmail.com
http://www.hh.um.es
Histology and
Histopathology
Cellular and Molecular Biology
GISTs and commonly originates in exon 18 (4-7%) and
exon 12 (2-6%) (Badalamenti et al., 2007; Gajiwala et
al., 2009; Blay, 2010). Nearly 10-15% of cases lack
mutations in both KIT and PDGFRA (wild-type GISTs)
(Agaimy et al., 2009; Gronchi et al., 2010), and a subset
of GISTs displays KIT and PDGFRA wild-type
activating mutations of the oncogene BRAF (Agaimy et
al., 2009; Martinho et al., 2009). 
Patients with exon 11 mutations have a better
response rate to imatinib than patients with exon 9
mutations or wild-type KIT (Badalamenti et al., 2007).
The role of the mutational status in patients’ response to
imatinib treatment is also observed by the resistance to
imatinib in association with gain of secondary KIT
mutations, mainly in exons 13 and 17, hampering the
therapeutic efficacy. Sunitinib and, more recently,
nilotinib, have been used to replace imatinib in the cases
of imatinib-resistant mutants (Gajiwala et al., 2009;
Gramza et al., 2009; Blay, 2010). 
Lymphatic and blood vessel invasion by cancer cells
are directly related with metastasis occurrence, and the
evaluation of vascular density is a useful parameter to
predict poor prognosis (Tammela and Alitalo, 2010).
Augmented lymphatic vessel density (LVD) is usually
associated with an aggressive behavior in the majority of
cancers that frequently use lymphatics, due to the fragile
structure of these vessels (Afonso et al., 2009). GISTs
preferentially invade and metastasize through blood
vessel conduits (Shinomura et al., 2005), although
recently the expression of lymphatic markers, such as
podoplanin / D2-40 (Kimura and Kimura, 2005; Yu et
al., 2007; Agaimy and Carney, 2010), was reported in
GISTs. Podoplanin is a transmembrane glycoprotein
expressed in a variety of human cell types, including
lymphatic endothelium. D2-40 is a commercially
available monoclonal antibody directed against human
podoplanin (Kalof and Cooper, 2009). GISTs’ lymph
nodal invasion has been reported in children and young
adults with the Carney triad (Agaimy and Carney, 2010).
Specific reasons for the high rate of tumoral lymphatic
spread in these paediatric GISTs patients are unknown. 
GISTs treatment was improved by the anti-tyrosine
kinase and anti-angiogenic drugs (McAuliffe et al.,
2007), but no evidence of lymphangiogenic associated-
proteins was reported in these tumours. 
The goal of this study was to characterise, in
molecularly characterized GISTs, the expressions of the
most potent lymphangiogenic protein and its receptor,
vascular endothelial growth factor (VEGF) -C and
VEGFR-3 (respectively), to assess tumoral LVD and
blood vessel density (BVD), and to correlate these
parameters with the clinical-pathological data.
Materials and methods
All of the patients with clinically diagnosed GISTs
were examined and surgically treated at Barretos Cancer
Hospital, State of São Paulo, Brazil, between 2000 and
2008. Clinical-pathological data were retrospectively
retrieved from the files of the hospital medical records.
Cases with history of previous cancer treatment were
excluded. The general information included tumoral
necrosis, ascites, distant metastases, time elapsed until
recurrence, survival rates and cause of death (when
death occurred). Tumours were classified in accordance
with the WHO criteria and the parameters analysed in
each case included age, gender, primary tumour site,
tumour size, histological type, mitotic index and risk
group (Miettinen et al., 2000; Fletcher et al., 2002). 
Follow-up data were available for all patients,
collected through direct interviews with patients or their
relatives and by reviewing the patients’ records. 
Tumoral persistence was defined as the presence of a
palpable mass seen at clinical follow-ups within the first
three months. Recurrence was defined as tumour
detection at a clinical follow-up after three months of
tumour absence.
DNA isolation
Tumoral areas containing at least 85% of tumour
tissue were macro-dissected into a microfuge tube using
a sterile needle (Neolus, 25G, 0.5 mm) and DNA
isolation was performed using Qiagen’s QIAamp® DNA
Micro Kit, as formerly described (Gomes et al., 2008;
Martinho et al., 2009). 
Mutation analysis on KIT, PDGFRA and BRAF genes
Evaluation of the hotspot regions affecting KIT
(exons 9, 11, 13 and 17), PDGFRA (exons 12, 14 and
18) and BRAF (exons 11 and 15) genes was conducted
by means of PCR followed by direct sequencing for
exons 9 and 11 of the KIT gene, and by means of PCR-
SSCP for the remaining regions, as previously described
(Gomes et al., 2008; Martinho et al., 2009). Samples
showing a mobility shift in the PCR-SSCP analysis that
differed from the normal pattern were directly sequenced
(Stabvida, Investigation and Services in Biological
Sciences Lda, Oeiras, Portugal). Additionally, analyses
of cryptic KIT exon 11 duplications were made using
specific PCR, followed by direct sequencing, as
previously reported (Martinho et al., 2009). All positive
cases were confirmed twice with a new and independent
PCR amplification, followed by direct sequencing.
Immunohistochemical reactions
CD117 immunohistochemistry 
Immunohistochemistry protocol was as previously
described (Gomes et al., 2008; Martinho et al., 2009).
Briefly, the reaction was performed using the
streptavidin-biotin-peroxidase complex, and a specific
antibody raised against CD117 (dilution 1:500, clone A
4502, DAKO, Carpinteria, Denmark). Sections were
semi-quantitatively scored as follows: (-), 0% presence
of immunoreactive cells; (+), <5% presence of
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immunoreactive cells; (++), 5-50% presence of
immunoreactive cells; and (+++), >50% presence of
immunoreactive cells. Samples with scores (-) and (+)
were considered negative, and those with scores (++)
and (+++) were considered positive.
VEGF-C, VEGFR-3, D2-40 and CD31 immunohisto-
chemistry
Table 1 was adopted from Afonso et al. (2009) and
summarizes the principal information of the
immunohistochemical reaction for VEGF-C, VEGFR-3,
D2-40 and CD31 antibodies. For all procedures, the
positive reactions were highlighted with diamino-
benzidine and substrate chromogen system,
DakoCytomation® (DAKO Corporation, Carpinteria,
CA, USA) incubated for 10 minutes at room
temperature. The positive expressions of VEGF-C and
VEGFR-3 were semi-quantitatively assessed using ?200
amplification. The positive reactions were assessed in
hotspot areas where GISTs cells and proliferating
vascular structures were present and stained. The
following grading system was used: negative (-),
absence of expression; slightly positive staining (+),
expression in up to 10% of cells; moderately positive
(++), expression in over 10% up to 50% of cells;
strongly positive (+++), expression in over 50% of cells. 
VEGF-C and VEGFR-3 strongly stained the
cytoplasm of malignant cells and infrequently stained
the endothelial cells. For this reason, only the positive
staining of malignant cells was considered for
evaluation.
Evaluation of vascular densities
The immunohistochemical evaluation of positive
reactions for D2-40 (for LVD assessment) and CD31
(for BVD assessment) was performed as postulated by
Weidner et al. (1991), with slight modifications. The
number of vessels was quantified at x 200 magnification.
A median of 10 hotspot fields was defined as vessel
density. The examination of each hotspot corresponds to
a number of vessels confined to an area of 0.15 mm2.
Both D2-40 and CD31 immunohistochemical positive
reactions were independently counted in blood and
lymphatic vessels from intratumoral and peritumoral
areas. Intratumoral area was defined as the stromal tissue
within two or more neoplastic aggregates, and
peritumoral area was defined as the stroma tissue
surrounding this neoplastic mass (Afonso et al., 2009).
D2-40 positivity in tumor cells was classified as negative
(negative or weak immunoreaction) and positive
(moderate to strong immunoreaction). 
Statistical analysis
The available clinical-pathological and immuno-
histochemistry data were analysed by means of the SPSS
software for Windows, version 17.0 (SPSS Inc.,
Chicago, IL, USA). Associations between categorical
variables were investigated using Fisher’s exact test. For
LVD and BVD analysis, the cut-off values that were
better correlated with tumour aggressiveness were
determined by ROC (receiver operating characteristic
curves) analysis. Cumulative survival probabilities were
calculated using the Kaplan-Meier method. Differences
between survival rates were tested by the log-rank test.
P-values lower than 0.05 were considered to be
significant. 
Results
Twenty six male (51.0%) and 25 female (49.0%)
patients were analysed. Ages were divided into ≤55
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Table 1. Summary of the methodological protocols used for VEGF-C, VEGFR-3, D2-40 and CD31 immunohistochemical procedures.
Antibodies VEGF-C VEGFR-3 D2-40 CD31
Antigen Recovery 600 W, 15 min 700 W, 15 min 600 W, 15 min 600 W, 10 min
Primary Antibody
Clone Z-CVF3, Zymed®
Laboratories (CA, USA)
Dilution: 1:70
Incubation: ON, 4ºC
Clone C234, Santa Cruz
Biotechnology®, Inc.
(Santa Cruz, CA, USA)
Dilution: 1:200
Incubation: 60 min, RT
Clone D2-40, DakoCytomation®
(DAKO Corporation,
Carpinteria, CA, USA) Dilution:
1:100
Incubation: ON, 4ºC
Clone JC70A,
DakoCytomation® (Denmark)
Dilution: 1:100
Incubation: 60 min, RT
Secondary Antibody
RTU Biotinylated Universal
Antibody, Vector®
(Vector Laboratories Inc.,CA,
USA)
Incubation: 30 min, RT
Goat Anti-Polyvalent,
Labvision®
(LabVision Corporation,
Fremont, CA)
Incubation: 10 min, RT
RTU Biotinylated Universal
Antibody, Vector®
(Vector Laboratories Inc.,CA, USA)
Incubation: 30 min, RT
Goat Anti-Polyvalent,
Labvision®
(LabVision Corporation,
Fremont, CA)
Incubation: 10 min, RT
Streptavidin Peroxidase /
Avidin-Biotin Complex
Vectastain RTU Elite ABC
reagent, Vector® Incubation:
45 min, 37ºC
Large volume Streptavidin
Peroxidase, Labvision®
Incubation: 10 min, RT
Vectastain RTU Elite ABC reagent,
Vector® Incubation: 45 min, 37ºC
Large volume Streptavidin
Peroxidase, Labvision®
Incubation: 10 min, RT
Positive Control Colon carcinoma Breast carcinoma Tonsil Breast carcinoma
W: watt; min: minutes; ON: overnight; RT: room temperature; RTU: ready-to-use; ABC: avidin-biotin complex.
years old (24, or 47.1%) or >55 years old (27, or 52.9%).
The primary sites of GISTs were stomach (27, 52.9%),
small intestine (11, 21.6%), colon and rectum (7,
13.7%), mesentery (2, 3.9%), retroperitoneum (3, 5.9%)
and rectovaginal area (1, 2.0%).
The term metastasis was used to categorise distant
neoplastic invasion. No lymph node invasion was
observed in this casuistic. Actually, in GIST surgery,
lymphadenectomy is not usually performed. Distant liver
metastasis was found in 16 cases, peritoneum invasion
was found in 13 patients and lung invasion was found in
just one case.
Mutation analysis of KIT, PDGFRA and BRAF
oncogenes 
The mutational status of GISTs showed KIT gene
alterations in 86.2% (44/51) of the cases, most of them
(72.5%, 37/51) revealing mutations in exon 11, followed
by mutations in exon 9 (9.8%, 5/51) and exon 17 (3.9%,
2/51) (Table 2). PDGFRA mutations were recognized in
7.8% (4/51) of the cases, exclusively observed in exon
18 (Table 2). None of the cases showed mutations of the
BRAF oncogenes; 11.0% of the cases (6/51) were wild-
type (Table 2). 
VEGF-C and VEGFR-3 expression
Table 3 shows the distribution of VEGF-C (Fig. 1)
and VEGFR-3 (Fig. 2) expression in malignant cell
according to the mutational status of GISTs. The
proteins’ positive reactions were constantly strong and
predominantly expressed in malignant cells’ cytoplasm.
Essentially, VEGF-C expression did not exhibit
significant differences among the molecular
characterization of GISTs. Conversely, VEGFR-3
appeared to be more importantly expressed in KIT and
PDGFRA mutated than in non-mutated cases (p=0.019).
Expression of VEGF-C and VEGFR-3 in lymphatic
vessels was not quantified due to the scarcity of positive
reactions. Additionally, Table 4 depicts the correlation
between both VEGF-C and VEGFR-3 expression, and
clinical-pathological parameters. No significant
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Fig. 1. Strong VEGF-C positive reaction in spindled GIST malignant
cells. x 200
Table 2. Molecular analysis of gastrointestinal stromal tumors.
Case KIT PDGFRA BRAF
1 Exon 11 (p.Trp557_Val559delinsCys) ND ND
2 Exon 11 (p.Trp557_Val559delinsCys) ND ND
3 Exon 11 (p.Trp557_Lys558del) ND ND
4 Exon 11 (p.Val560Glu) ND ND
5 Exon 11 (p.Trp557_Lys558del) ND ND
6 Exon 11 (p.Leu576Pro) ND ND
7 Exon 11 (p.Trp557_Val559delinsCys) ND ND
8 Exon 11 (p.Val559Asp) ND ND
9 Exon 11 (p.Tyr553_Lys558del) ND ND
10 Exon 11 (p.Trp557_Lys558del) ND ND
11 Exon 11 (p.Gln556_Glu561delinsPro) ND ND
12 Exon 11 (p.Pro585Thr) ND ND
13 Exon 11 (p.Val559Asp) ND ND
14 Exon 11 (p.Val559Asp) ND ND
15 Exon 11 p.Trp557_Glu561del) ND ND
16 Exon 11 (p.Glu554_Ile571del) ND ND
17 Exon 11 (p.Val560Asp) ND ND
18 Exon 11 (p.Asp579Asn) ND ND
19 Exon 11 (p.Lys558delinsAsnPro) ND ND
20 Exon 11 (p.Lys550_Trp557delinsIleLeu) ND ND
21 Exon 11 (p.Trp568_Gln575delinsSer) ND ND
22 Exon 11 (p.Trp557_Lys558del) ND ND
23 Exon 11 (p.Val559Asp) ND ND
24 Exon 11 (p.Trp557_Val559delinsCys) ND ND
25 Exon 11 (p.Trp557_Val559delinsCys) ND ND
26 Exon 11 (p.Trp557_Lys558del) ND ND
27 Exon 11 (p.Trp557Arg) ND ND
28 Exon 11 (p.Pro573_Arg586dup) ND ND
29 Exon 11 (p.Leu576Pro) ND ND
30 Exon 11 p.Trp557_Lys558del) ND ND
31 Exon 11 (p.Trp557_Lys558del) ND ND
32 Exon 11 (p.Trp557_Lys558del) ND ND
33 Exon 11 (p.Lys558_Val559delinsAsn) ND ND
34 Exon 11 (p.Trp557del) ND ND
35 Exon 9 (p.Ala502_Tyr503dup; p.Val473Met) ND ND
36 Exon 9 (p.Ala502_Tyr503dup) ND ND
37 Exon 9 (p.Ala502_Tyr503dup) ND ND
38 Exon 9 (p.Ala502_Tyr503dup) ND ND
39 Exon 9 (p.Ala502_Tyr503dup) ND ND
40 Exon 17 (p.Asp820Tyr) ND ND
41 Exon 17 (p.Asp820Tyr) ND ND
42 Wild Type Exon 18 (p.Asp842Val; p.Asp842Glu)ND
43 Wild Type Exon 18 (p.Asp842Val) ND
44 Wild Type Exon 18 (p.Asp842Val) ND
45 Wild Type Exon 18 (p.Asp842_Ile843delinsVal) ND
46 Wild Type Wild Type Wild Type
47 Wild Type Wild Type Wild Type
48 Wild Type Wild Type Wild Type
49 Wild Type Wild Type Wild Type
50 Wild Type Wild Type Wild Type
51 Wild Type Wild Type Wild Type
ND: not done
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Fig. 5. Endothelial cells from blood vessels stained with CD31 antibody.
x 200
Fig. 3. D2-40 positive reaction in GIST malignant cells. x 200
Fig. 4. Lymphatic vessels density in GIST. Endothelial cells from
lymphatic vessels are stained with D2-40 antibody. x 200
Fig. 2. Strong VEGFR-3 positive reaction in GIST malignant cells. x 200
Table 3. Association between GIST genetic status and VEGF-C and VEGFR-3 immunohistochemical positive reactions.
VEGF-C VEGFR-3
Total Positive (%) p* Total Positive (%) p*
GIST †
With KIT/PDGFRA mutation 41 22 (53.7) 0.476 39 39 (100) 0.093
Wild-type 1 0 (0.0) 4 3 (75.0)
Mutation
Wild-type 1 0 (0.0) 0.391 4 3 (75.0) 0.019
KIT exon 9 5 2 (40.0) 5 5 (100)
KIT exon 11 30 15 (50.0) 29 29 (100)
KIT exon 17 2 2 (100) 1 1 (100)
PDGFRA exon 18 4 3 (75.0) 4 4 (100)
*: p< 0.05; †: Fisher exact test.
association was observed, although VEGFR-3
expression showed a tendency to be associated with
higher risk of malignancy (considering Fletcher
classification) (p=0.059).
Lymphatic and blood vessel density
D2-40 immunoreactivity was observed in both
malignant (Fig. 3) and endothelial cells from lymphatic
vessels (Fig. 4). CD31 immunoreactivity was only
assessed in blood vessels (Fig. 5).
The cut-off values (determined by ROC analysis) for
LVD (assessed by D2-40 immunoreactivity) and BVD
(assessed by CD31 immunoreactivity) were 3.2 and 7.4,
respectively (considering intratumoral and peritumoral
vascular counting). Peritumoral D2-40 positive reactions
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Table 4. Association between GIST clinical-pathological parameters and VEGF-C and VEGFR-3 immunohistochemical positive reactions.
VEGF-C VEGFR-3
Total Positive (%) p* Total Positive (%) p*
Ascites†
Presence 9 5 (55.6) 1.000 9 9 (100) 1.000
Absence 33 17 (51.5) 34 33 (97.1)
Fletcher Risk of Malignancy
Very Low/ Low 6 3 (50.0) 0.927 6 5 (83.3) 0.059
Moderate 12 7 (58.3) 12 12 (100)
High 21 11 (52.4) 21 21 (100)
Loco-regional Recidive §†
Presence 7 5 (71.4) 0.407 6 6 (100) 1.000
Absence 18 9 (50.0) 20 19 (95.0)
Cancer Persistence
Yes 17 8 (47.1) 0.569 17 17 (100) 1.000
No 25 14 (56.0) 26 25 (96.2)
Metastasis
Presence 19 11 (57.9) 0.516 20 20 (100) 1.000
Absence 23 11 (47.8) 23 22 (95.7)
Tumor size (cm)
<10 21 11 (52.4) 0.882 23 22 (95.7) 1.000
≥10 18 9 (50.0) 17 17 (100)
Mitotic index  (per field)†
≤5 28 15 (53.6) 0.956 28 27 (96.4) 1.000
>5 11 6 (54.5) 11 11 (100)
Necrosis†
Presence 30 16 (53.3) 0.845 30 29 (96.7) 1.000
Absence 12 6 (50.0) 13 13 (100)
*: p<0.05; †: Fisher exact test; §: the cases with no persistent disease were also analyzed.
Table 5. Association between GIST mutation status and D2-40 (for lymphatic vessel density assessment) and CD31 (for blood vessel density
assessment) immunohistochemical positive reactions.
Lymphatic Vessels density (D2-40) Blood Vessels Density (CD31)
Total >3.2 (%) p* Total >7.4 (%) p*
GIST †
With KIT/PDGFRA mutation 40 21 (52.5) 0.607 40 26 (65.0) 0.651
Wild-type 5 1 (33.3) 5 4 (80.0)
Mutation
Wild-type 5 1 (33.3) 0.936 5 4 (80.0) 0.398
KIT exon 9 4 2 (40.0) 4 3 (75.0)
KIT exon 11 31 16 (55.2) 31 18 (58.1)
KIT exon 17 1 1 (50.0) 1 1 (100)
PDGFRA exon 18 4 2 (50.0) 4 4 (100)
*: p<0.05; †: Fisher exact test.
were rarely observed. High LVD (>3.2) did not correlate
with the molecular genetic status (Table 5). Regarding
the clinical-pathological parameters, high LVD was
correlated with the absence of metastasis (p=0.010)
(Table 6); in contrast, BVD was associated with the
occurrence of GISTs’ metastases (p=0.049).
Discussion
The results herein reported corroborate, in part, the
statement that GISTs’ metastasis occurs preferentially
through blood vessels (Miettinen et al., 2005). Our data
did not show any appreciable parameter to correlate the
lymphatic vessel net with the clinical-pathological
variables of tumour aggressiveness. However, we
observed that VEGF-C, which is believed to be
essentially a powerful cancer lymphangiogenic factor,
and its preferential receptor VEGFR-3, are consistently
expressed by GIST cells. Intriguingly, the expression of
VEGFR-3 was significantly correlated with the presence
of KIT mutations, but did not correlate with the clinical
variables, which leads us to suppose that GIST cancer
cells are able to up-regulate VEGF-C and VEGFR-3
expression, although these molecules do not influence
lymphatic vessel proliferation in these tumours. 
In the present study, we found a statistical
correlation between KIT/PDGFRA mutations and
VEGFR3 expression. Despite the absence of published
data on such correlating, some studies found a positive
association between VEGFR3 expression and activating
mutations of oncogenes downstream of the KIT and
PDGRA pathway, such as KRAS, suggesting that
constitutive activating of receptor tyrosine kinase
signaling can lead to VEGFR3 overexpression
(Schimanski et al., 2010).
Our results have shown that GIST malignant cells
remarkably express both lymphangiogenic molecules,
which suggests that these molecules can be involved
with the regulation of other structures, likely blood
vessels. GISTs are highly vascularised tumours and
metastasis generally occurs through the blood vessel net.
Many cancer cells express VEGFR-3, but the function of
this receptor is imprecise. Paradoxically, VEGF-
C/VEGFR-3 activity can be associated with the
development of angiogenic sprouts, mainly in
association with COX2 upregulation (Chien et al., 2009).
The widespread distribution of VEGF-C/VEGFR-3 in
GISTs observed in this series encourages us to
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Table 6. Association between GIST clinical-pathological parameters and D2-40 (for lymphatic vessel density assessment) and CD31 (for blood vessel
density assessment) immunohistochemical positive reactions.
Lymphatic Vessels density (D2-40) Blood Vessels Density (CD31)
Total >3.2 (%) p* Total >7.4 (%) p*
Ascites†
Presence 9 4 (44.4) 0.454 9 5 (55.6) 0.454
Absence 34 18 (52.9) 36 25 (69.4)
Fletcher Risk of Malignancy
Very Low/ Low 6 5 (83.3) 0.200 9 6 (66.7) 0.117
Moderate 12 7 (58.3) 11 11 (91.7)
High 21 9 (42.9) 21 12 (57.1)
Loco-regional Recidive §†
Presence 7 5 (71.4) 1.000 7 6 (85.7) 1.000
Absence 19 12 (63.2) 22 18 (81.8)
Cancer Persistence
Yes 17 -- (--) -- 18 11 (61.1) 0.519
No 26 -- (--) 27 19 (70.4)
Metastasis
Presence 20 6 (30.0) 0.010 24 20 (83.3) 0.049
Absence 23 16 (69.6) 18 10 (55.6)
Tumor size (cm)
<10 23 13 (56.5) 0.337 28 19 (67.9) 1.000
≥10 17 7 (41.2) 12 8 (66.7)
Mitotic index (per field)†
≤5 27 15 (55.6) 0.748 14 11 (78.6) 0.321
>5 12 6 (50.0) 31 19 (61.3)
Necrosis†
Presence 13 8 (61.5) 0.370 9 5 (55.6) 0.454
Absence 30 14 (46.7) 36 25 (69.4)
*: p< 0.05; †: Fisher exact test; §: the cases with no persistent disease were also analyzed.
hypothesise that VEGF-C/VEGFR-3 favour the
improvement of blood vessel densities. Favouring this
angiogenic hypothesis, we observed high blood vessel
densities in intra and peritumoral area. Additionally,
high BVD was related to metastatic status. Cases with
high level of BVD assessed with CD31 monoclonal
antibody and VEGF upregulation were identified as poor
prognostic GISTs (Imamura et al., 2007).
Blood vessel density, however, is not necessarily
guaranteed to ascertain tumour aggressiveness.
Paradoxically, a high BVD could be related to a lesser
metastatic potential if the new blood vessels are
predominantly weak, distorted and exhibit defects of
vascular assembly (Afonso et al., 2009). In our casuistic,
conversely, BVD was associated with metastasis
occurrence, which reinforces the premise that BVD
correlates with GISTs’ aggressiveness.
The expression of D2-40 in GISTs has been recently
investigated, but no informative assessment is yet
available to improve knowledge of GIST behaviour
(Kimura and Kimura, 2005; Yu et al., 2007; Agaimy and
Carney, 2010). In Carney triad patients, intra-tumoral
lymphangiogenesis was not confirmed to be responsible
for GISTs’ lymphatic spread, usually observed in this
group; also, the biological meaning of D2-40 expression
in GIST cells is not fully understood (Agaimy and
Carney, 2010). We observed a remarkable D2-40
positive immunoreaction in GIST cells, but we failed to
understand the implication of this finding in these
tumours. Kuroda et al. (2008) suggested that D2-40
expression may be an available marker of GISTs, but is
definitely not associated with the degree of risk of
GISTs’ aggressiveness. 
Our results were corroborated, in part, by Mahendra
and colleagues (2008) who observed that, except in a
few types of sarcomas (epithelioid, leiomyosarcoma,
rhabdomyosarcoma and synovial sarcoma) lymphatics
are usually absent in most of the malignant soft tissue
tumours, which is consistent with the infrequent finding
of sarcoma metastasis to lymph nodes. 
Altogether, our findings have detailed for the first
time in literature, to the best of our knowledge, the
distribution of the lymphangiogenic promoter VEGF-C
and its receptor VEGFR-3 in GISTs. The strong
expression of both markers was not necessarily
correlated with the clinical parameters of aggressiveness,
but BVD was importantly correlated with metastasis.
One can speculate that both lymphangiogenic markers
may be more closely associated with angiogenesis than
lymphangiogenesis in GISTs. Further studies should be
planned to investigate this hypothesis. 
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